The US Food and Drug Administration has almost 30 new molecular entity and novel biologics under review with user fee goal dates in the second half of 2019, which all but guarantees a modest annual approval count following on the record high of 2018.
The staggering approval count for 2018 was always going to be hard to match: 65 novel agents were approved last year, including the most ever for the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?